NMRA PE Ratio & Valuation,Is NMRA Overvalued

NMRA Relative Valuation

NMRA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NMRA is overvalued; if below, it's undervalued.

Historical Valuation

Neumora Therapeutics Inc (NMRA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.87. The fair price of Neumora Therapeutics Inc (NMRA) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：2.09

Fair

-1.77

-1.07

EV/EBITDA

Neumora Therapeutics Inc. (NMRA) has a current EV/EBITDA of -1.07. The 5-year average EV/EBITDA is -3.64. The thresholds are as follows: Strongly Undervalued below -10.36, Undervalued between -10.36 and -7.00, Fairly Valued between -0.28 and -7.00, Overvalued between -0.28 and 3.08, and Strongly Overvalued above 3.08. The current Forward EV/EBITDA of -1.07 falls within the Historic Trend Line -Fairly Valued range.

-1.06

EV/EBIT

Neumora Therapeutics Inc. (NMRA) has a current EV/EBIT of -1.06. The 5-year average EV/EBIT is -3.61. The thresholds are as follows: Strongly Undervalued below -10.26, Undervalued between -10.26 and -6.93, Fairly Valued between -0.28 and -6.93, Overvalued between -0.28 and 3.04, and Strongly Overvalued above 3.04. The current Forward EV/EBIT of -1.06 falls within the Historic Trend Line -Fairly Valued range.

0.00

Neumora Therapeutics Inc. (NMRA) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

-2.14

P/OCF

Neumora Therapeutics Inc. (NMRA) has a current P/OCF of -2.14. The 5-year average P/OCF is -6.10. The thresholds are as follows: Strongly Undervalued below -14.91, Undervalued between -14.91 and -10.51, Fairly Valued between -1.70 and -10.51, Overvalued between -1.70 and 2.71, and Strongly Overvalued above 2.71. The current Forward P/OCF of -2.14 falls within the Historic Trend Line -Fairly Valued range.

-2.49

P/FCF

Neumora Therapeutics Inc. (NMRA) has a current P/FCF of -2.49. The 5-year average P/FCF is -5.84. The thresholds are as follows: Strongly Undervalued below -13.81, Undervalued between -13.81 and -9.83, Fairly Valued between -1.86 and -9.83, Overvalued between -1.86 and 2.12, and Strongly Overvalued above 2.12. The current Forward P/FCF of -2.49 falls within the Historic Trend Line -Fairly Valued range.

Neumora Therapeutics Inc (NMRA) has a current Price-to-Book (P/B) ratio of 2.55. Compared to its 3-year average P/B ratio of 3.19 , the current P/B ratio is approximately -19.88% higher. Relative to its 5-year average P/B ratio of 3.19, the current P/B ratio is about -19.88% higher. Neumora Therapeutics Inc (NMRA) has a Forward Free Cash Flow (FCF) yield of approximately -58.58%. Compared to its 3-year average FCF yield of -44.00%, the current FCF yield is approximately 33.15% lower. Relative to its 5-year average FCF yield of -44.00% , the current FCF yield is about 33.15% lower.

2.55

P/B

Median3y

3.19

Median5y

3.19

-58.58

FCF Yield

Median3y

-44.00

Median5y

-44.00

Competitors Valuation Multiple

The average P/S ratio for NMRA's competitors is 12.36, providing a benchmark for relative valuation. Neumora Therapeutics Inc Corp (NMRA) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of NMRA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of NMRA in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Neumora Therapeutics Inc (NMRA) currently overvalued or undervalued?

What is Neumora Therapeutics Inc (NMRA) fair value?

NMRA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Neumora Therapeutics Inc (NMRA) is between to according to relative valuation methord.

How does NMRA's valuation metrics compare to the industry average?

The average P/S ratio for NMRA's competitors is 12.36, providing a benchmark for relative valuation. Neumora Therapeutics Inc Corp (NMRA) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Neumora Therapeutics Inc (NMRA) as of Dec 15 2025?

As of Dec 15 2025, Neumora Therapeutics Inc (NMRA) has a P/B ratio of 2.55. This indicates that the market values NMRA at 2.55 times its book value.

What is the current FCF Yield for Neumora Therapeutics Inc (NMRA) as of Dec 15 2025?

As of Dec 15 2025, Neumora Therapeutics Inc (NMRA) has a FCF Yield of -58.58%. This means that for every dollar of Neumora Therapeutics Inc’s market capitalization, the company generates -58.58 cents in free cash flow.

What is the current Forward P/E ratio for Neumora Therapeutics Inc (NMRA) as of Dec 15 2025?

As of Dec 15 2025, Neumora Therapeutics Inc (NMRA) has a Forward P/E ratio of -1.77. This means the market is willing to pay $-1.77 for every dollar of Neumora Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Neumora Therapeutics Inc (NMRA) as of Dec 15 2025?

As of Dec 15 2025, Neumora Therapeutics Inc (NMRA) has a Forward P/S ratio of 0.00. This means the market is valuing NMRA at $0.00 for every dollar of expected revenue over the next 12 months.

NMRA Valuation